MannKind Corporation announced that it has received a Complete Response letter from the U.S. Food & Drug Administration …
Insulin
FDA Accepts Biodel’s New Drug Application for Review
Biodel Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new d…
FDA Clears Clibra’s Insulin Patch
Calibra Medical Inc., formerly known as Seattle Medical Technologies Inc., announced today that the U.S. Food and Drug A…
FDA Needs More Time to Review MannKind’s New Drug Application for Inhaled Insulin
MannKind Corp. announced that it was informed today by the FDA that they will not be able to complete the review of Mann…
Biodel Inc. Submits New Drug Application to FDA for A New Form of Insulin
Biodel, Inc. announced that it has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for c…
Is Lantus Insulin Linked to Increased Risk of Cancer? New Study Begins
Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade nam…
Eli Lilly Announces The First 300-Unit Vial of Insulin
Eli Lilly and Company announced the availability of a smaller vial of insulin containing 3 mL (300 units), the first suc…
Novo Nordisk Starts Phase 1 Trial With Oral Insulin
Novo Nordisk announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN195…
Novo Nordisk: Progress Made in Oral Insulin Development
Lars Sorensen, Novo's chief executive, speaking at the Reuters Health Summit, said the company could introduce a oral in…
